Investing.com - Verona Pharma (NASDAQ:VRNA) ADR reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Verona Pharma ADR announced earnings per share of $0.02 on revenue of $40M. Analysts polled by Investing.com anticipated EPS of $-0.1922 on revenue of $0.00.
Verona Pharma ADR shares are down 26.14% from the beginning of the year, still down 46.82% from its 52 week high of $9.72 set on February 25. They are under-performing the Nasdaq which is up 24.01% from the start of the year.
Verona Pharma ADR follows other major Healthcare sector earnings this month
Verona Pharma ADR's report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Pfizer had beat expectations on November 2 with third quarter EPS of $1.34 on revenue of $24.09B, compared to forecast for EPS of $1.08 on revenue of $22.58B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar